| Active substance | isatuximab |
| Holder | Sanofi Belgium |
| Status | closed |
| Indication | in combination with pomalidomide and dexamethasone (Isa-Pd) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 10/08/2022 |